Deep-pocketed investors have adopted a bullish approach towards AbbVie ABBV, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in ABBV usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options activities for AbbVie. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 45% leaning bullish and 27% bearish. Among these notable options, 3 are puts, totaling $207,332, and 8 are calls, amounting to $422,158.
Projected Price Targets
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $125.0 to $210.0 for AbbVie over the last 3 months.
Volume & Open Interest Trends
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for AbbVie's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of AbbVie's whale activity within a strike price range from $125.0 to $210.0 in the last 30 days.
AbbVie Option Volume And Open Interest Over Last 30 Days
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ABBV | PUT | SWEEP | BEARISH | 01/16/26 | $16.05 | $16.05 | $16.05 | $175.00 | $134.3K | 730 | 118 |
| ABBV | CALL | SWEEP | BULLISH | 01/16/26 | $9.6 | $8.7 | $9.6 | $195.00 | $96.8K | 3.5K | 123 |
| ABBV | CALL | SWEEP | BULLISH | 05/16/25 | $4.2 | $3.95 | $4.11 | $190.00 | $89.9K | 1.4K | 219 |
| ABBV | CALL | TRADE | BULLISH | 02/21/25 | $3.6 | $3.0 | $3.6 | $180.00 | $72.0K | 3.5K | 217 |
| ABBV | PUT | SWEEP | BEARISH | 06/20/25 | $8.5 | $8.25 | $8.5 | $170.00 | $42.5K | 932 | 61 |
About AbbVie
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
After a thorough review of the options trading surrounding AbbVie, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
Where Is AbbVie Standing Right Now?
- With a trading volume of 1,402,809, the price of ABBV is down by -1.12%, reaching $176.5.
- Current RSI values indicate that the stock is may be approaching overbought.
- Next earnings report is scheduled for 21 days from now.
What The Experts Say On AbbVie
In the last month, 2 experts released ratings on this stock with an average target price of $215.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access. * Consistent in their evaluation, an analyst from Truist Securities keeps a Buy rating on AbbVie with a target price of $211. * An analyst from Piper Sandler persists with their Overweight rating on AbbVie, maintaining a target price of $220.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest AbbVie options trades with real-time alerts from Benzinga Pro.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
